CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 97 filers reported holding CABALETTA BIO INC in Q3 2023. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $319,057 | +23.6% | 20,963 | +4.8% | 0.00% | – |
| Q2 2023 | $258,200 | -42.9% | 20,000 | -63.4% | 0.00% | – |
| Q1 2023 | $452,344 | -57.5% | 54,697 | -52.4% | 0.00% | – |
| Q4 2022 | $1,063,547 | +1511.4% | 114,978 | +13.7% | 0.00% | – |
| Q3 2022 | $66,000 | -95.0% | 101,100 | -91.9% | 0.00% | – |
| Q2 2022 | $1,330,000 | -55.6% | 1,254,479 | -15.0% | 0.00% | -100.0% |
| Q1 2022 | $2,994,000 | -49.5% | 1,475,100 | -5.7% | 0.00% | 0.0% |
| Q4 2021 | $5,925,000 | -20.9% | 1,563,523 | +153.8% | 0.00% | 0.0% |
| Q3 2021 | $7,490,000 | +1218.7% | 615,967 | +832.8% | 0.00% | – |
| Q2 2021 | $568,000 | +171.8% | 66,032 | +250.3% | 0.00% | – |
| Q1 2021 | $209,000 | +54.8% | 18,851 | +74.4% | 0.00% | – |
| Q4 2020 | $135,000 | +13.4% | 10,809 | -33.7% | 0.00% | – |
| Q1 2020 | $119,000 | – | 16,312 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
| COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
| VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
| Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
| Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
| Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
| TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
| Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |